Shire Acquires Foresight Biotherapeutics for $300 Million
The acquisition strengthens Shire’s ophthalmics portfolio.
Shire has acquired New York-based, privately held Foresight Biotherapeutics for $300 million. The acquisition strengthens Shire’s position in ophthalmics. Shire will hold global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine [PVP-I] and 0.1% dexamethasone), a therapy in late-stage development for the treatment of infectious conjunctivitis. This move is a boost to Shire’s late-stage pipeline and has a clear strategic fit with lifitegrast, which is in late-stage development for treatment of dry eye disease.
The approval of FST-100 would make it the first treatment for both bacterial and viral eye infections, transforming treatment of acute conjunctivitis. With global rights to FST-100, Shire will evaluate an appropriate regulatory filing strategy for additional markets outside the United States. Under the terms of the agreement, Shire will make a cash payment of $300 million to complete the acquisition of Foresight Biotherapeutics.
Source: Shire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
